New cancer drug tested in Head-to-Head trial
Disease control
Completed
This study compared a new drug called RPH-002 to an existing drug, Erbitux®, for people with advanced head and neck cancer that had returned or spread. The main goals were to see if the body processed the two drugs similarly and to check their safety when given with standard chem…
Phase: PHASE1 • Sponsor: R-Pharm • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC